RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer.

Kim, Sang T; Murphy, William A; Aparicio, Ana; Subudhi, Sumit K

Kim, Sang T; Murphy, William A; Aparicio, Ana; Subudhi, Sumit K.

Afiliação

Kim ST; Department of General Internal Medicine, Section of Rheumatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Murphy WA; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aparicio A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Subudhi SK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

J Immunother Precis Oncol ; 3(3): 128-132, 2020 Aug.

Article em En | MEDLINE | ID: mdl-35663254

Palavras-chave

RS3PE; checkpoint inhibitors; immune-related adverse events; ipilimumab; prostate cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Immunother Precis Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google